Professional Documents
Culture Documents
Plot No . F/11 & F/ 12, WICEL, Opp. SEEPZ Main Gate, Central Road, Andheri (E}, Mumbai-4?0 093, India .
T : +91 22 6700 1000 I F : +91 22 2832 4404 I E: corporate@camlinfs.com I www.camlmfs.com
ISO 22000 Certified Company
CIN L7 41OOMH1993PLC075361
Date: 2410512016
To,
BSE Limited,
25, P. J. Towers,
Dalal Street,
Mumbai - 400 00 l
Ref: Company Scrip Code: 532834
To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd. ,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Ref: Symbol: CAMLINFINE 11 Series: EQ
Sub:
This is to inform you that the senior management team of the Company shall engage in
meetings with domestic and international institutional investors and analysts amongst
others in major investor hubs from May 25, 2016 upto June 06, 2016.
In this regard, please find attached a presentation prepared by the Company. It is clarified
that the presentation and the information contained therein does not constitute or form
part of an invitation or solicitation to offer to purchase or subscribe to any securities of
the Company in any jurisdiction. This presentation has been prepared for information
purposes only. The information contained in the investor presentation is not to be taken
as any recommendation made by the Company or any other person to enter into any
agreement with regard to any investment.
We request you to take the above on record and the same be treated as compliance under
the applicable Regulations of SEBI LODR.
Kindly take the above information on records.
Thanking You,
Encl.: a/a.
~cesLimited
Rahul D. Sawal
Group Compa Secretary
Shelflifesolutions|PerformanceChemicals|AromaChemicals
Corporate Presentation
CorporatePresentation
May 24 2016
May24,2016
Disclaimer
Thispresentationisconfidentialandmaynotbecopied,published,distributedortransmitted.TheinformationinthispresentationisbeingprovidedbyCamlinFineSciencesLimited(alsoreferredto
asCompany).Byattendingameetingwherethispresentationismade,orbyreadingthispresentationmaterial,youagreeto be boundbyfollowinglimitations:
TheinformationinthispresentationhasbeenpreparedforuseinpresentationsbyCompanyforinformationpurposesonlyanddoesnotconstitute,orshouldberegardedas,orformpartofany
offer,invitation,inducementoradvertisementtosellorissue,oranysolicitationoranyoffertopurchaseorsubscribefor,anysecuritiesoftheCompanyinanyjurisdiction,includingtheUnitedStates
andIndia,norshallit,orthefactofitsdistributionformthebasisof,orbereliedoninconnectionwith,anyinvestmentdecisionoranycontractorcommitmenttopurchaseorsubscribeforany
securitiesoftheCompanyinanyjurisdiction,includingtheUnitedStatesandIndia.Thispresentationdoesnotconstitutea recommendationbytheCompanyoranyotherpartytosellorbuyany
securitiesoftheCompany.
Thispresentationanditscontentsarenotandshouldnotbeconstruedasaprospectusoranofferdocument,includingasdefinedundertheCompaniesAct,2013,totheextentnotifiedandinforceor
anofferdocumentundertheSecuritiesandExchangeBoardofIndia(IssueofCapitalandDisclosureRequirements)Regulations,2009asamended.
TheCompanymayalter,modify,orotherwisechangeinanymannerthecontentsofthispresentationwithoutobligationtomodifyanypersonofsuchchangeorchanges.
Norepresentationorwarranty,expressorimplied,ismadeasto,andnorelianceshouldbeplacedon,thefairness,accuracy,completenessorcorrectnessoftheinformationoropinionscontainedin
No
representation or warranty express or implied is made as to and no reliance should be placed on the fairness accuracy completeness or correctness of the information or opinions contained in
thispresentation.NeitherCompanynoranyofitsaffiliates,advisorsorrepresentativesshallhaveanyresponsibilityorliabilitywhatsoever(fornegligenceorotherwise)foranylosshowsoeverarising
fromanyuseofthispresentationoritscontentsorotherwisearisinginconnectionwiththispresentation.Theinformationset outhereinmaybesubjecttoupdating,completion,revision,verification
andamendmentandsuchinformationmaychangematerially.Thispresentationisbasedontheeconomic,regulatory,marketandotherconditionsasineffectonthedatehereof.Itshouldbe
understoodthatsubsequentdevelopmentsmayaffecttheinformationcontainedinthispresentation,whichneitherCompanynorits affiliates,advisorsorrepresentativesareunderanobligationto
update,reviseoraffirm.
ThispresentationcontainscertainsupplementalmeasuresofperformanceandliquiditythatarenotrequiredbyorpresentedinaccordancewithIndianGAAP,andshouldnotbeconsideredasan
This
presentation contains certain supplemental measures of performance and liquidity that are not required by or presented in accordance with Indian GAAP and should not be considered as an
alternativetoprofit,operatingrevenueoranyotherperformancemeasuresderivedinaccordancewithIndianGAAPoranalternativetocashflowfromoperationsasameasureofliquidityofthe
Company.
Youmustmakeyourownassessmentoftherelevance,accuracyandadequacyoftheinformationcontainedinthispresentationandmustmakeindependentanalysisasyoumayconsidernecessary
orappropriateforsuchpurpose.Anyopinionsexpressedinthispresentationaresubjecttochangewithoutnoticeandpastperformanceisnotindicativeoffutureresults.Byattendingthis
presentationyouacknowledgethatyouwillbesolelyresponsibleforyourownassessmentofthemarketpositionoftheCompanyandthatyouwillconductyourownanalysisandbesolely
responsible for forming your own view of the potential future performance of the Companyssbusiness.
responsibleforformingyourownviewofthepotentialfutureperformanceoftheCompany
business
ThispresentationcontainsforwardlookingstatementsbasedonthecurrentlyheldbeliefsandassumptionsofthemanagementoftheCompany,whichareexpressedingoodfaithand,intheir
opinion,reasonable.Forwardlookingstatementsinvolveknownandunknownrisks,uncertaintiesandotherfactors,whichmaycausetheactualresults,financialcondition,performance,or
achievementsoftheCompanyorindustryresults,todiffermateriallyfromtheresults,financialcondition,performanceorachievementsexpressedorimpliedbysuchforwardlookingstatements.The
risksanduncertaintiesrelatingtothesestatementsinclude,butarenotlimitedto,risksanduncertaintiesregardingexpansionplansandthebenefitstherefrom,fluctuationsinourearnings,our
abilitytomanagegrowthandimplementstrategies,competitioninourbusinessincludingthosefactorswhichmayaffectourcost advantage,wageincreasesinIndia,ourabilitytoattractandretain
hi hl kill d
highlyskilledprofessionals,ourabilitytowinnewcontracts,changesintechnology,availabilityoffinancing,ourability
f i
l
bilit t i
t t h
i t h l
il bilit f fi
i
bilit to
t successfullycompleteandintegrateourexpansionplans,liabilities,political
f ll
l t
di t
t
i
l
li biliti
liti l
instabilityandgeneraleconomicconditionsaffectingourindustry.Unlessotherwiseindicated,theinformationcontainedherein ispreliminaryandindicativeandisbasedonmanagement
information,currentplansandestimates.Industryandmarketrelatedinformationisobtainedorderivedfromindustrypublicationsandothersourcesandhasnotbeenverifiedbyus.Giventhese
risks,uncertaintiesandotherfactors,recipientsofthisdocumentarecautionednottoplaceunduerelianceontheseforwardlookingstatements.TheCompanydisclaimsanyobligationtoupdate
theseforwardlookingstatementstoreflectfutureeventsordevelopments.
ThispresentationisnotanofferforsaleofsecuritiesintheUNITEDSTATESorelsewhere.
CamlinFineSciencesLimited(CFS)
Leveraging core competencies to address a large target market
Leveragingcorecompetenciestoaddressalargetargetmarket
CFS Providingshelflifesolutionsalongwitharomaandperformance
chemicalstotargetlargeenduserindustries
ShelflifeSolutions
PerformanceChemicals
Aromachemicals
Shelflifeextensionproducts
Presence
Presenceinantioxidantsandintermediates
in antioxidants and intermediates
forfood,feed,petfoodandanimalnutrition
Food
Petfood
Pharmaintermediates
Agrochemicals
Feed&food
Consumergoods
AnimalNutrition
Rendering
Dyesandcolours
Petrochemicals
IncenseSticks
Flavours&Fragrances
AquaCulture
Biofuels
Pharmaceuticals
CFS'productsfindapplicationsinwidespectrumofproductsinfood,animalnutrition,petfood,consumergoodsandindustrialuses
CFS|Keystrengthsanddifferentiators
Globalplayerinshelflifesolutions
acrossfood,feedandpetfood
f d f d d tf d
Strongfinancialsandcash
flows
Experiencedpromotersand
Experienced
promoters and
professionalmanagementteam
Localpresenceinglobalmarkets
Provenabilitytoacquireand
Proven
ability to acquire and
improvebusinessperformance
Diversifiedcustomerbase
AdvancedR&Dfacilities
Globalplayerinshelflifesolutionsandintermediatesforfood,feedand
petfood
Strongpresenceinbasicfoodgrade1 antioxidants;graduallyexpandingintoblends
Globalantioxidants
l b l
i id
(industrysizeof~US$3.2bn)
Naturalantioxidants
Syntheticantioxidants
Blends
TBHQ+BHA
Xtendra
/NaSure
Source:Technavio
1 includesfood,feedandpetfood
5
Diversifiedproductbase
Acrossantioxidant,aromaandperformancechemicalssegments
CFSproductportfolio
Others:1%
Aroma:3%
Segment
Product
Applications
Diphenols
Catechol
HQ
TBHQ
Food and feed antioxidant to extend shelf life of products; used for stabilizing oils,
fats butter
fats,
b tter & margarine
mar arine
BHA
Food and feed antioxidant to extend shelf life of products; used for stabilizing oils,
fats, butter & margarine
BHT
A
AscorbylPalmitate
b l P l it t
Antioxidant
A ti id t for
f sensitive
iti products
d t like
lik baby
b b food,
f d instant
i t t milk
ilk formula
f
l
Blends
Antioxidants to extend shelf life of food, feed and pet food products
Guaiacol
Veratrole
TBC
Stabilization of monomers
MEHQ
OtherHQand
Catecholderivatives
Vanillin/
Ethyl Vanillin
Aroma compound in flavour and fragrances; Agro, Feed & Food, Consumer Goods
& Healthcare
Others
Diphenols:18%
Antioxidants
PerformanceChemicals:22%
Performance
Chemicals
Antioxidants:56%
Aroma
Chemicals
Revenue (FY16)
Revenue(FY16)
compound
used
in
Pharma,
Fullyintegratedacrossthevaluechain
Ensuresbettercontrolonsupplychain,realizationsandmargins
KeyRawMaterial
Commodity
chemical
Phenol
Versalis; Novapex
CFSEurope
Diphenols
Eastman;Mitsui
Hydroquinone
Catechol
Solvay/Rhodia;Ube
OtherCFSgroupentities1
Performance
Chemicals
ShelfLifeSolutions
Aroma
AscorbylPalmitate
A
b l P l it t 2
TBHQ
G i l
Guaiacol
MEHQ
V illi
Vanillin
Blends
BHA
Veratrole
OtherderivativesofHQ
EthylVanillin
Otherderivativesof
Other
derivatives of
Catechol
Fullyintegratedfromdiphenolstostepdownderivatives,antioxidantblendsandVanillintherebyreducingriskofsupplychaindisruptions
1IncludesproductsmanufacturedthroughcontractmanufacturingforCFS
2
AscorbylPalmitateisnotapartofHQ/Catecholvaluechainandismanufacturedfromascorbicacid
7
Localpresenceinglobalmarkets
OngroundpresenceinAmericaandEuropewithstrongIndiafootprint
Geographicalreachacrosskeymarkets
Denmark
Netherlands
UnitedKingdom
Ravenna,Italy
Tarapur
Iowa,USA
Shanghai,China
Cuba
Mexicocity
Khopoli
p
Mahad
Guatemala
Mumbai
Columbia
Peru
OwnedPlants
Indaiatuba,Brazil
OutsourcedManufacturing
BlendingFacility
R&D/FoodLabs
Marketingoffices
CFSglobalfootprintisexpectedtoimproveordersfromglobalMNCswhoprefertheirsupplierstohavelocalpresenceacrossgeographies
Diversifiedcustomerbase
Acrosscustomersgeographiesandenduserindustries
Revenuebasediversifiedacrossgeographies
Goingforwarddiversificationshouldincreasefurther
Currently ~56% revenues are from food grade antioxidants;
Performance
Chemicals
(PC)
contributes
to
~22%
of
revenues, Diphenols (HQ & Catechol) constituted ~18% while Aroma
Chemicals (Vanillin) is at an early stage contributing ~3% of FY16
revenues
5%
9%
31%
11%
FY16
Revenues
19%
25%
Europe
AsiaPacific(exc.India)
India
South&CentralAmerica
NorthAmerica
Others
Revenuebasediversifiedacrossgeographiesandcustomers;acquisitionofDresenQuimicaisexpectedtofurtherdiversifyrevenuebase
ContinuousinvestmentsinR&Dacrossgeographies
R&Dfacilitiesacrosstheworldwith#34scientistsacross2R&Dlabsand4ApplicationLabs
R&DLabs
Iowa,USA
Ravenna,Italy
ApplicationLabs
Mumbai,India
Developing customized
various applications
Tarapur,India
blends
for
Mexicocity
defined
performance
Indaiatuba,Brazil
10
hasenabledprocessimprovementsandglobalcertifications
ApprovalforgreenprocesstomanufactureGuaiacol
Ex ONCBroute
(concernsonbeingcarcinogenic
andenvironmentallyharmful)
Chlorobenzene
ONCB
O anisidine
Oanisidine
Guaiacol
Benzene
Ex Catecholroute
(believedtobe
environmentfriendly)
Phenol
Catechol
Vanillin
PatentappliedforbyCFS
ProcessusedbyCFS
CFShasappliedforpatentoftheenvironmentallyfriendlyexCatecholprocess,whichisapreferredapproachformanufacturingofVanillin
Majorcertifications
ISO 2008
ISO2008
ISO 2005
ISO2005
Kosher
BHA&TBHQ
FSAAI certificate
FSAAIcertificate
11
Kosher
Vanillin&TBC
Halal certificate
Halalcertificate
Provenabilitytoacquireandturnaroundbusinesses
CFSacquisitionandturnaroundofItaliansubsidiarywaswellconceivedandexecuted
Demonstratedexperienceinacquiringandintegratingcompanies
Acquiredin2011
At acquisition, Borregaards Italian subsidiary was engaged in the manufacturing of HQ
and Catechol
The acquisition gave CFS a significant presence in the European market; helped CFS
backward integrate to secure the sources of HQ and Catechol for global operations
Companys first international acquisition
At acquisition it had a capacity of 6,600MTPA which has been increased to 12,000MTPA
through debottlenecking and incremental capex
AcquisitionofCFSEurope,Borregaards
ItaliansubsidiaryforEUR1.4mn
Revenueshavegrownsubstantially
withsignificantimprovementinPATmargins
INRmn
10.8%
2,973
2,289
2,258
7.9%
1,881
1,467
3.6%
FY12
FY13
FY14
FY15
FY16
0.4%
0.4%
FY12
FY13
FY14
FY15
CFS'acquisition,turnaroundandintegrationofCFSEuropeisareflectionofthemanagementcapabilitiesofCFSteam
12
FY16
Leadershipteamacrosstheglobetoaddresscustomerdemandslocally
CFStopmanagementoperatesfromacrosstheworld
JackBoers
SeniorVP AntioxidantStrategy
andBusinessDevelopment
dB i
D l
JorgenSorensen
Global VP Antioxidants
GlobalVP
SandraGrossmann
GlobalBusinessDevelopment Petfood
CFSNorthAmerica
AnneMetteFrost
GlobalApplicationManager
JenniferIgou
VP Sales,
CFSNorthAmerica
R.ShivKumar
GeneralManager
ArturoJavierDvilaCabrera
VP Sales,
VP
Sales
Mexico,CentralAmerica
LucianodosSantosMonteiro
Luciano
dos Santos Monteiro
GeneralManager,SouthAmerica
AshishDandekar
hi h
d k
ManagingDirector,CFS
AntonioMenezes
ManagingDirector,CFSEurope
13
Experiencedleadershipteam
Experiencedleadershipteam
AnneMette Frost
GlobalApplication
Global
Application
Manager
AntonioMenezes
Managing
Director,CFS
Europe
JJorgen Sorensen
S
GlobalVP
Antioxidants
ArturoJavierDvila
Cabrera
VPSalesMexico,
CentralAmerica
JackBoers
SeniorVP
Antioxidant
Strategy&Business
Development
JenniferIgou
Jennifer
Igou
VP Sales,
CFSNorthAmerica
LucianodosSantos
Monteiro
GeneralManager,
SouthAmerica
R.Shiv Kumar
GeneralManager
g
SandraGrossmann
Sandra
Grossmann
GlobalBusiness
Dev. Petfood
CFSNorthAmerica
14
Robustfinancialprofile1
CFSIncome hasgrownsteadily
withimprovingEBITDAmargins
Revenues(INRmn)
...thathasledtohealthyoperatingcashflows
EBITDAmargin(%)
19.1%
5,087
3,352
5,583
4,893
14.9%
3,736
16.2%
CFO(INRmn)
556
600
463
463
400
267
13.8%
200
12.0%
0
(200)
(400)
FY12
FY13
FY14
FY15
FY16
FY12
Ithasconsistentlyreducedleverage
FY13
FY14
FY15
FY16
evenwhileincreasingassetbase
Debt/Equityratio
(319)
FY12
FY13
FY14
FY15
thussupportingimprovementinitsratios
NetFixedAssets
RoCE
2.4
,
1,653
1.9
25%
20%
1.6
1,052
1.2
761
0.9
1,092
15%
840
10%
5%
0%
FY12
FY13
FY14
FY15
FY16
FY12
FY13
FY14
FY15
FY16
FY12
FY13
FY14
CFSaimstoincreaseitsprofitabilityfurther,bymovingupthevaluechainandincreasedcapacityutilization
1
Consolidatedfinancials;
TotaldebtforFY12FY15includescurrentportionofLTDebt;forFY16thedebtnumberdoesntincludethecurrentportionofLT Debt
RoCE iscalculatedasEBIT/AverageCapitalEmployed;EBITDAincludesOtherIncomeandmarginsarecalculatedongrossbasis
15
FY15
FY16
Futuregrowthstrategy
16
KeygrowthdriversforCFS
Focusonblendsforfood,feedand
pet food
petfood
Capacityexpansionthroughnew
plantatDahejSEZ
ScaleVanillinbusiness
Increasedrevenuefrom
introductionofnewderivativesof
HQandCatechol
LeverageMexicoacquisitionto
expandpresence&productbasket
17
Focusonsyntheticandnaturalblendsforfood,feedandpetfood
Blendsmarketofferslargeopportunities
antioxidantblendsforfood,feedandpetfood
NaturalVanilla
NaturalBlends
((industrysizeof~8,000MTPA)
y
f ,
)
SyntheticBlends
CFS has started focusing on this segment recently and intends to gain market share
Productportfolioincludingproductsinanimalnutritionsegmentacquiredaspartof
acquisitionofDresen,Mexico
18
ScaleVanillinbusiness
FocusonandgrowtheVanillinbusiness
Vanillaflavor/fragrance
(naturalandsynthetic)
NaturalVanilla
SyntheticVanilla
ExONCBprocess
Excatecholprocess
(potentiallycarcinogenic;lesscosteffective;higher
pollution)
(preferredmanufacturingroute;constrainedby
availabilityofCatechol)
Fragmentedmarket
DominatedbyplayerswithaccesstoCatechol
Vanillin
EthylVanillin
CFS,withaccesstoCatechol, issettingupown/contractmanufacturingcapacitytomanufactureVanillinandEthylVanillin
19
Increasedrevenuecontributionfromperformancechemicalsbusiness
Performancechemicalspresentalargeopportunity
Revenuecontributionfromperformance chemicalshasincreasedover
thelast2years
and CFSisimplementingplanstokeepgrowingatafastpace
0.6% 1%
Antioxidants
13%
29%
FY14
FY14
Revenues
Diphenols
Create distribution hubs in keyy markets like North America,, Asia and
Latin America and leverage on its presence in these markets
Performance Chemicals
PerformanceChemicals
57%
Aroma
Otherproducts
22%
FY16
Revenues
18%
PerformanceChemicals
56%
Aroma
Otherproducts
CFSaimstogrowtheportfoliotoincreaseitsmarketshareinperformancechemicals
Note:PC PerformanceChemicals
20
LeverageMexicoacquisitiontoexpandpresence&productbasket
MexicoacquisitionofferssignificantsynergieswithCFS
Abouttheacquisition
US$000s
CY14
CY15
CFS,
CFS through
th
h a WOS,
WOS acquired
i d 65% off Dresen
D
Q i i for
Quimica
f a consideration
id ti off USD 7.8mn
78
N tS l
NetSales
14 799
14,799
16 458
16,458
975
2,012
6.6%
12.2%
1,283
2,625
8.7%
16.0%
6,563
7,889
Operating Profit%
PBT
PBT%
The transaction was completed earlier in May and full impact of the same will be visible in quarter
ended September 30, 2016
AboutDresen
Leading
Central
American
company
engaged
research,
h development,
d l
manufacture
f
and
d sale
l off specialty
l chemicals
h
l
OperatingProfit
NetWorth
Potential synergieswithCFS
in
Crosssell products Dresen has a well regarded animal nutrition business and CFS
willll market
k the
h same across other
h geographies;
h
similarly
l l CFS products
d
can be
b
marketed by Dresen
the
Improved vertical integration Dresen uses the diphenols as raw materials; the
acquisition helps Dresen secure raw material and secures supply contracts for CFS
Animal
Feed
and
Human
Food
segment
manufactures
adsorbents, antioxidants, bactericides, binders, mold inhibitors and acidifying
agents; one of the larger suppliers in its key markets
Improved margins for CFS on account of higher value addition done by Dresen
Improved geographical reach to service global MNCs locally
Technical knowhow in animal nutrition which can be leveraged across the CFS group
to provide better products and services to customer
Strategically located manufacturing facility
MexicoofferssignificantsynergieswithCFSandcanimproveCFSproductbasket,geographicalreachandprofileamongstpotentialcustomers
21
ProposedexpansionatDahejplant
KeycharacteristicsoftheproposedplantatDahej
Particulars
Details
Productparticulars
Capacity
Proposedarea fortheplant
DahejSEZ,Gujarat
Landarea
67,507squaremeters
Overallplant
(current thoughtprocess)
Expectedlocationadvantages
Expected commissioning
Expectedcommissioning
Availabilityofkeyrawmaterialsinvicinity
Situatednearportsandgoodconnectivity
Goodinfrastructure
Conduciveforfutureexpansion
Advantageousfortaxandexcisebenefits asit
isinaSEZ
Commoneffluenttreatment plant
HQanditsderivatives
Catecholanditsderivatives
Vanillin
ProposedCapacityforkey products
Product
HQ 9,000MTPA
Catechol/Vanillin 6,000MTPA
FY18
Expectedyearofcommercial FY19
production
Status ofproject
Basic engineeringcompleted;Detailed
g
g g g
engineeringongoing
Environmentapproval Awaited
TheplantatDahejwillexpandcapacitiesandprovideCFSwithabasetomanufactureHQ,CatecholandVanillininIndia
22
Annexure
23
CamlinFineSciences(CFS)|Aquickintroduction
CompanyOverview
Q and BHA
One of the leadingg manufacturers of TBHQ
NetSales
Global reach through manufacturing plants across India, Europe, Latin America with customers across
key markets
EBITDA
Summaryfinancials(INRmn)
Marquee client base; enduses across Food, Pet food, Animal feed, Vanillin and Performance Chem.
Sharepriceperformance CFS1
Shareholding(asatMarch31,2016)
130
PAT%
NetWorth
NetDebt2
100
Promoters
90
InstiInvestors
80
FY15
FY16
5,087
5,583
4,893
713
925
961
13.8%
16.2%
19.1%
287
550
358
5.6%
9.6%
7.1%
933
1,349
1,762
1,341
1,407
1,4833
Otherdetails
Fitch : LT Ind A; ST Ind A1
39 8%
39.8%
110
Auditors
Exchanges listed
Others
70
60
Market Cap1
55.7%
50
PAT
Credit Rating
120
Jan15
EBITDA%
FY14
4.5%
May15
Sep15
Jan16
May16
DatafromBSELtd.asonMay22,2016
2NetDebtforFY14andFY15includescurrentportionofLTDebt
DuringtheFY16thereisachargeforINR45.47mnduetoshortreceiptofinsuranceclaimrelatingtoafirewhichoccurredduringFY14
EBITDAincludesotherIncome.Marginsarecalculatedongrossbasis
SBT StateBankofTravancore;SBI StateBankofIndia;SBP StateBankofPatiala;OBC OrientalBankofCommerce
24
INR 9,100mn
Thestorysofar
2016
2015
2014
2012
2011
2009
2006
Acquisition of 65% stake in Dresen Quimica S.A.P.I.de C.V., Mexico along with its 5
subsidiaries in Mexico, Peru, Guatemala, Columbia and Dominican Republic
The acquisition has helped the company to expand its market reach in Central and
South America and parts of Latin America
ListedontheNationalStockExchange
ForayedintoblendsbusinessinUSA
Startedmanufacturing&marketingofcustomizedblendsinTarapurandBrazil
SetupApplicationlaboratoriesfullysupportedbyanexperiencedtechnicalteam
LaunchedAromaandFlavoringCompounds Vanillin/EthylVanillin
AcquiredCFSEuropeS.p.A
BecameanintegratedmanufacturerofDiphenols
LaunchedawiderangeofPerformanceChemicalslikeMEHQ,Veratrole,Guaiacoletc.
Becamesignificantproduceroffoodantioxidantsglobally:TBHQ&BHA
PartofCamlinGroup,namechangedtoCamlinFineChemicalsPvt.ltd
BecameapubliclimitedCompany(CFCL)
DemergedfromCamlinLimitedandlistedontheBombayStockExchange
25
Currententitystructure
CamlinFineSciencesLtd.
100%
CFCLMauritiusPvt.Ltd.
(Mauritius Holdco.)
100%
100%
CFSdoBrasilIndstria,
Comrcio,ImportaoE
ExportaoDeAditivos
Alimentcios Ltd (Brazil)
AlimentciosLtd.(Brazil)
SubsidiaryinBrazilfor
manufacturingand
marketingofblends
100%
100%
CFSNorthAmericaLLC.
(U.S.A.)
SolentusNorthAmerica
Inc.(Canada)
SubsidiaryinUSAfor
manufacturingand
marketingofblends
SubsidiaryinCanadafor
marketingofblends
100%
CFSAntioxidantesDe
MexicoS.A.DeC.V
(Mexico HoldCo.)
100%
CFSInternationalTrading
(Shanghai)Ltd.
(China)
65%
DresenQuimicaS.A.P.l.
deC.V.(Mexico)
100%
100%
Nuvel,S.A.C
(Peru)
Britec,S.A
(Guatemala)
Parentcompany
Subsidiaries/Stepdownsubsidiaries
StepdownsubsidiariespursuanttoMexicoacquisition
26
100%
lnovel,S.A.S.
(Columbia)
100%
Grinel,S.A
(DominicanRepublic)
ReputedDirectorsontheBoard
DilipD.Dandekar
Chairman&Non
ExecutiveDirector
PramodM.Sapre
IndependentDirector
SharadM.Kulkarni
IndependentDirector
Leena Dandekar
WholetimeDirector
BhargavA.Patel
IndependentDirector
DattatrayaR.Puranik
ExecutiveDirector&CFO
Has been the CFO of the Company since 2008 and Executive Director
and CFO since 2012
AbeezarE.Faizullabhoy
IndependentDirector
NirmalV.Momaya
NonExecutiveDirector
AjitS.Deshmukh
NonExecutiveDirector
AtulR.Pradhan
IndependentDirector
NicolaA.Paglietti
IndependentDirector
27
Productvaluechain
Valuechainofkeyproducts
Phenol
Hydroquinone
AscorbicAcid
Ascorbyl
Palmitate
TBHQ
BHA
MEHQ
Catechol
Other
derivativesof
HQ
Q
Blends
28
Veratrole
Guethol
Guaiacol
EthylVanillin
Vanillin
Other
derivativesof
Catechol
Catec
o
Profit&LossSnapshot(consolidated)
Particulars(INRmn)
FY12A
FY13A
FY14A
FY15A
FY16A
3,352
3,736
5,087
5,583
4,893
11.5%
36.1%
9.8%
(12.3%)
CostofMaterialsConsumed
1,675
1,646
2,757
2,705
2,031
EmployeeBenefitExpenses
243
302
344
406
410
1,141
1,318
1,369
1,630
1,534
ProfitfromOperationsbeforeOtherIncome,Dep.Interest&Exceptional Item
293
470
616
842
918
Add: OtherIncome(Expenses)
116
102
97
84
43
EBITDA
409
572
713
925
961
12.0%
14.9%
13.8%
16.2%
19.1%
Less:Depreciationandamortizationexpenses
135
136
118
162
171
OperatingProfit(EBIT)beforeexceptionalitems
274
436
595
763
790
Financecosts
167
201
247
238
244
p
ProfitBeforeTaxesbeforeexceptionalitems
107
235
349
525
546
(1)
(4)
451
108
235
349
528
500
Less:IncomeTaxExpense
69
84
61
(22)
142
39
39
151
151
287
287
550
550
358
358
Profit&LossfromAssociates
(1)
(0)
(0)
(0)
(0)
NetIncomeAfterMinorities
38
151
287
550
358
NetRevenuefromoperations
Salesgrowth%
Less: Expenses
Less:Expenses
OtherExpenses
EBITDAMargin%
Less:ExceptionalItems
ProfitfromOrdinaryActivitiesbeforetax
DuringtheFY16thereisachargeforINR45.47mnduetoshortreceiptofinsuranceclaimrelatingtoafirewhichoccurredduringFY14
29
BalanceSheet(consolidated)
Particulars(INRmn)
FY12A
FY13A
FY14A
FY15A
FY16A
529
654
933
1,349
1,762
330
330
377
377
285
285
281
281
214
214
Short TermDebt
885
795
1,040
1,210
1,457
33
31
(40)
52
51
AccountsPayable
872
1,575
1,000
1,066
953
OtherCurrentLiabilities(includingcurrentmaturities ofLTDebt)
206
263
428
340
389
2,856
3,695
3,647
4,297
4,827
761
840
1,052
1,092
1,653
26
22
27
217
176
Inventory
844
1,490
1,092
1,364
1,733
AccountsReceivable
902
871
,
1,013
1,134
,
755
LoansandAdvancesandOtherCurrentAssets
222
214
304
296
320
CashandCashEquivalents
102
257
158
193
189
TotalApplicationofFunds
2,856
3,695
3,647
4,297
4,827
NetWorth
Debt
OtherLongTermLiabilities
Currentliabilities
TotalLiabilitiesandEquity
NetFixedAssets
OtherLongTermAssets
CurrentAssets
30
Glossaryofterms
Termsused
Inference
HQ
Hydroquinone
TBHQ
TertiaryButylHydroquinone
BHA
ButylatedHydroxyanisole
ODEB
OrthoDiethoxyBenzene
MEHQ
HydroquinoneMonoMethylEther
ASP
AscorbylPalmitate
ONCB
OrthoNitroChloroBenzene
BHT
Butylated HydroxyToluene
PC
PerformanceChemicals
US$
USDollar
INR
IndianRupee
mn/Mn
Million
CAGR
CompoundedAnnualGrowthRate
FY
12monthsendingMarch31ofthementionedyear
CY
12monthsending December31ofthementionedyear
MTPA
MetricTonnesPerAnnum
Di h
Diphenols
l
HQ d Catechol
HQand
C
h l
31
Thankyou
32